TRAVERE THERAPEUTICS

Travere Therapeutics to Present at Upcoming Investor Conferences

25 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 11 2024 17:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

12 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

07 11 2024 21:05:37 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

07 11 2024 16:01:18 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

04 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2024 Financial Results

31 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

26 10 2024 07:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2024 Financial Results

21 10 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

17 10 2024 07:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

14 10 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

26 9 2024 16:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 9 2024 17:00:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

10 9 2024 16:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

05 9 2024 17:34:13 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

22 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

06 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2024 Financial Results

01 8 2024 16:01:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2024 Financial Results

25 7 2024 16:30:00 提供 Nasdaq GlobeNewswire

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

08 7 2024 16:30:00 提供 Nasdaq GlobeNewswire